Nanosomix Announces New Blood Test For Use By Alzheimer’s Disease Researchers

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ALISO VIEJO, Calif.--(BUSINESS WIRE)--A new blood test reliably predicts whether a person is likely to develop Alzheimer’s Disease (AD) up to 10 years before the disease is diagnosed, according to a multi-site study recently published in the Alzheimer’s Association journal Alzheimer’s & Dementia.

The study was conducted by Ed Goetzl, M.D. and others. Researchers used a unique approach to identify and isolate a well-known neural biomarker called p-tau, which previously had not been detectable in blood. Study results showed that the assay could correctly classify 96.4% of AD cases and could identify pre-symptomatic patients up to 10 years prior to diagnosis. Consisting of two phases, the study involved a total of 162 subjects, half of them Alzheimer’s disease patients and half of them controls.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC